20th week of 2014 patent applcation highlights part 40 |
Patent application number | Title | Published |
20140134127 | Protein-Polymer-Drug Conjugates - A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L | 2014-05-15 |
20140134128 | MULTIMERIC IL-15 SOLUBLE FUSION MOLECULES AND METHODS OF MAKING AND USING SAME - The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus). | 2014-05-15 |
20140134129 | RNA Vaccines - A RNA vaccine containing a RNA molecule encoding an allergen or derivative thereof, in which the allergen is an allergen of | 2014-05-15 |
20140134130 | FUSED BICYCLIC OXALAMIDE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C - Compounds of Formula I, including pharmaceutically acceptable salts thereof, as well as compositions containing these compounds, have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: | 2014-05-15 |
20140134131 | Immune Regulation - A method of regulating the immune system of a subject that involves removing antigen presenting cells from subject and loading preselected class II peptide fragments onto the subjects APC's outside the body of the subject. | 2014-05-15 |
20140134132 | CYCLIC PEPTIDES AND USE AS MEDICINES - The present invention provides a compound of formula I; | 2014-05-15 |
20140134133 | HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS AND METHODS OF USE - The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans. | 2014-05-15 |
20140134134 | USE OF A COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN FOR THERAPEUTIC TREATMENT - The present invention relates to therapeutic use of a combination of Myxoma virus, including in combination with rapamycin. Treatment with rapamycin enhances the ability of Myxoma virus to selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon. The combination of rapamycin and Myxoma virus can be used to treat diseases characterized by the presence of such cells, including cancer. The invention also relates to therapeutic use of Myxoma virus that does not express functional M135R. | 2014-05-15 |
20140134135 | METHODS AND COMPOSITIONS FOR PRESERVING LEAN BODY MASS DURING WEIGHT LOSS - The invention provides compositions and methods for preserving lean body mass during weight loss in an animal. The methods comprise administering OEA to the animals, preferably in amounts of from about 0.01 to about 1000 mg/kg/day. | 2014-05-15 |
20140134136 | COMPOSITIONS AND METHODS FOR AUDITORY THERAPY - The invention provides compositions for inducing expression in hair cells, and provides methods of using these compositions for modulating cochlear expression. Such compositions are further useful in treatment of sensorineural hearing loss, e.g., increasing proliferation or survival of mechanosensory hair cells. | 2014-05-15 |
20140134137 | Use of Stem Cells to Reduce Leukocyte Extravasation - The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in leukocytes. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential. | 2014-05-15 |
20140134138 | Novel Use of Cryptotanshinone - Provided are a composition for stimulating differentiation of MSCs into osteoblasts, which includes cryptotanshinone, and an osteogenesis stimulator including cryptotanshinone and MSCs. When the cryptotanshinone is treated to the MSCs, the differentiation into osteoblasts is stimulated, and thus osteogenesis of a patient may be stimulated by directly transplanting the differentiation-induced MSCs to the patient. Accordingly, the composition or osteogenesis stimulator may be used to treat patients having disability requiring stimulation of osteogenesis such as osteoporosis, bone fracture, bone grafting including alveolar bone grafting for implant placement, or other bone defects. | 2014-05-15 |
20140134139 | CD34+ CELLS AND METHODS OF USE - Disclosed herein is a reprogrammed endothelial progenitor cell, said cell comprises a bone marrow-derived cell expressing the CD34+ marker and at least one cardiomyocyte-specific gene, as well as methods for preparing and using the same for cardiac regenerative medicine. | 2014-05-15 |
20140134140 | MESENCHYMAL STEM CELL COMPOSITIONS FOR THE TREATMENT OF MICROBIAL INFECTIONS - A method of treating a microbial infection in a subject includes administering to the subject a therapeutically effective amount of MSCs and an antimicrobial agent, wherein the MSCs potentiate the therapeutic activity of the antimicrobial agent, and the therapeutically effective amount is the amount effective to inhibit microbial growth and suppress microbial infection associated inflammation in the subject. | 2014-05-15 |
20140134141 | HUMAN FACILITATING CELLS - The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs. | 2014-05-15 |
20140134142 | Multi-Chain Chimeric Antigen Receptor and Uses Thereof - The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs. Such CARs, which aim to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties, comprise separate extracellular ligand binding and signaling domains in different transmembrane polypeptides. The signaling domains are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer and viral infections. | 2014-05-15 |
20140134143 | VECTORS AND METHODS FOR THE EFFICIENT GENERATION OF INTEGRATION/TRANSGENE-FREE INDUCED PLURIPOTENT STEM CELLS FROM PERIPHERAL BLOOD CELLS - A vector for generating induced pluripotent stem cells from human target cells comprising a) a vector backbone, b) exactly two, three or four transcription and reprogramming factor genes, each gene separated by a 2a self-cleavage peptide sequence, c) a spleen focus-forming virus promoter, and d) a post-transcriptional regulatory element Wpre, with or without an anti-apoptotic factor gene. A method for generating integration-free induced pluripotent stem cells, the method comprising: a) providing target cells, b) providing one or more than one vector according to the present invention, c) transducing or transfecting the target cells with the one or more than one vector, and d) culturing the transduced or transfected cells in a cell culture, thereby generating integration-free induced pluripotent stem cells. | 2014-05-15 |
20140134144 | USE OF PROBIOTIC BACTERIAL STRAINS AS A PROPHYLACTIC TOOL AGAINST UTERINE INFECTIONS IN PREGNANT FEMALE RUMINANTS - A method of treating uterine infections in a female bovine includes the step of, prior to parturition, intravaginally administering the female bovine with one or more bacterial strains such as | 2014-05-15 |
20140134145 | METHOD TO INDUCE AND EXPAND THERAPEUTIC ALLOANTIGEN-SPECIFIC HUMAN REGULATORY T CELLS IN LARGE-SCALE - Methods for inducing, expanding, and/or generating alloantigen-specific regulatory T cells. Alloantigen-specific regulatory T cells can be induced, expanded, and/or generated from naive CD4 | 2014-05-15 |
20140134146 | POLYSILOXANE-BASED FOULING RELEASE COATS INCLUDING ENZYMES - The present application discloses a fouling release cured paint coat comprising a polysiloxane-based binder matrix constituting at least 40% by dry weight of the coat, and one or more enzymes. The application further discloses a kit for preparing a fouling release coat, a coating composition comprising a polysiloxane-based binder system comprising one or more polysiloxane components modified with hydrophilic oligomer/polymer moieties, and one or more enzymes, and a coating composition comprising a polysiloxane-based binder system, 0.01-20% by dry weight of one or more hydrophilic-modified polysiloxane oils, and one or more enzymes. | 2014-05-15 |
20140134147 | N-TERMINAL DERIVATISATION OF PROTEINS WITH POLYSACCHARIDES - The present invention relates to methods for producing N-terminal derivatives of proteins in which a polysaccharide, preferably having at least terminal sialic units and preferably consisting essentially only of sialic acid units, is reacted at the N-terminus of a protein or peptide under controlled conditions to produce an N-terminal derivative. The controlled conditions include use of acidic pH for the derivatisation step and a higher pH for purification. The derivatives are useful for improving pharmacokinetics and pharmacodynamics of proteins and peptides. | 2014-05-15 |
20140134148 | Brucella Abortus Proteins and Methods of Use Thereof - Compositions and methods for the diagnosis and prevention of | 2014-05-15 |
20140134149 | ENZYMES FOR INHIBITING GROWTH OF BIOFILMS AND DEGRADING SAME - Enzymes for inhibiting growth of biofilms and degrading biofilms. The enzymes comprise glycosyl hydrolases capable of degrading biofilms. The enzymes are formulated in compositions with and without antimicrobial agents. The enzymes with and without the antimicrobial agents are delivered to biofilms to degrade the biofilms and treat infections of microorganisms associated with the biofilms, delivered to surfaces to inhibit growth of biofilms thereon, and administered to animals to inhibit growth of biofilms therein. | 2014-05-15 |
20140134150 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES - Microspheres are produced by contacting an aqueous solution of a protein or other macromolecule with an organic solvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals of defined dimensions. | 2014-05-15 |
20140134151 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS - The present invention relates to antidotes of anticoagulants targeting factor Xa which antidotes are used in combination with blood coagulating agents or other heparin antidotes to prevent or reduce bleeding in a subject. The antidotes described herein have reduced or no intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is or will be undergoing anticoagulant therapy with a factor Xa inhibitor. | 2014-05-15 |
20140134152 | COMPOSITIONS AND METHODS FOR TREATING DIABETES - Embodiments of the present invention relate to compositions and methods of treating patients for type 1 diabetes mellitus (T1D) by administering a therapeutically effective dose of recombinant human KLK1, variants of KLK1, or active fragments thereof. Such patients may be increase risk patients for developing T1D or T1D patients in the Honeymoon Phase. Such treatment may be expected to prevent or delay the onset of T1D, to ameliorate the symptoms of T1D, or to ameliorate the extent to which the T1D manifests. | 2014-05-15 |
20140134153 | ANTIMICROBIAL AGENT AND METHOD FOR PRODUCING THE SAME - [Problem] To provide: an antimicrobial agent which utilizes an antimicrobial activity and a pharmacological activity of a plant belonging to the family Juncaceae, comprises a material produced by seeding a seed culture of mushroom mycelia to a plant belonging to the family Juncaceae, culturing the mycelium while adding a nutrient source to thereby proliferate the mycelium and then drying the proliferated mycelium, can exhibit an excellent antimicrobial activity even when used in a small amount, can be added to a food, can be sprayed onto an agricultural crop or soil, and can be used as a therapeutic agent for athlete's foot; and a method for producing the antimicrobial agent. [Solution] A plant belonging to the family Juncaceae which is cut into a predetermined length or which is cut into a predetermined length and then milled is mixed with a nutrient source for a seed culture of mushroom mycelia, and the seed culture of mycelia is inoculated to the mixture of the plant belonging to the family Juncaceae and the nutrient source and then cultured at a growth temperature for the seed culture of mycelia for a predetermined time period. | 2014-05-15 |
20140134154 | Immunological Compositions as Cancer Biomarkers and/or Therapeutics - The present invention concerns antibodies that react immunologically with anti-tumor antigen antibodies and compositions and methods related thereto. In particular, the antibodies that react immunologically with the anti-tumor antigen antibodies are employed in therapeutic, diagnostic, and prognostic embodiments related to cancer, including breast cancer, for example. | 2014-05-15 |
20140134155 | Antibodies against prostate-specific stem cell antigen and use thereof - The invention relates to recombinant antibodies which bind to prostate-specific stem cell antigen (PSCA). The antibody of the invention comprises complementarity-determining regions (CDR) having the following amino acid sequences: CDR of the variable region of the light chain: CDR1 SEQ ID No. 1, CDR2 SEQ ID No. 2, CDR3 SEQ ID No. 3, and CDR of the variable region of the heavy chain: CDR1 SEQ ID No. 4, CDR2 SEQ ID No. 5, CDR3 SEQ ID No. 6. The invention also embraces the use of the antibodies of the invention as medicinal products, especially for the treatment of tumour diseases, or as a diagnostic agent. The antibodies are suitable for use in the areas of medicine, pharmacy and biomedical research. | 2014-05-15 |
20140134156 | ANIMAL MODELS AND THERAPEUTIC MOLECULES - The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods. | 2014-05-15 |
20140134157 | ANTIBODIES TO OPGL - Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described. | 2014-05-15 |
20140134158 | KRAS MUTATIONS AND RESISTANCE TO ANTI-EGFR TREATMENT - The disclosure provides compositions and methods for detecting and predicting acquired resistance to anti-EGFR treatment in colorectal cancers. Also provided are compositions and methods of preventing, reversing or delaying the acquired resistance. The present disclosure also provides kits for use in the methods described herein. | 2014-05-15 |
20140134159 | METHODS OF TREATING NEUROENDOCRINE TUMORS USING FRIZZLED-BINDING AGENTS - Novel methods of treating neuroendocrine tumors are provided. In one embodiment, the method comprises administering to a subject in need thereof a therapeutically effective dose of a Wnt antagonist. In one embodiment, the Wnt antagonist is an anti-FZD antibody. In another embodiment, the Wnt antagonist is a soluble FZD receptor polypeptide. In a further embodiment, the Wnt antagonist is an anti-Wnt antibody. | 2014-05-15 |
20140134160 | GEMCITABINE PRODRUGS AND USES THEREOF - The present invention provides compounds according to formula I: | 2014-05-15 |
20140134161 | EGFR TARGETED THERAPY - The present invention relates to compositions and methods for treatment of neurological disorders. In particular, the present invention relates to EGFR as a clinical target for treatment of neurological disorders. | 2014-05-15 |
20140134162 | Methods for the Treatment of Disease Using Immunoglobulins Having Fc Regions with Altered Affinities for FcgammaRactivating and FcgammaRinhibiting - The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds an FcγR that activates a cellular effector (“FcγR | 2014-05-15 |
20140134163 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS - Provided is a method of treating a proliferative disease, condition, or disorder in a subject by administering a combination of an inhibitor of p53 and MDM2 binding and an EGFR inhibitor. Various embodiments of the disclosed methods provide a synergistic anti-proliferative or anti-apoptotic effect compared to administration of one agent alone. | 2014-05-15 |
20140134164 | TREATMENT OF MULTIPLE SCLEROSIS - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 2014-05-15 |
20140134165 | Identification of Tumor-Associated Markers for Diagnosis and Therapy - The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases. | 2014-05-15 |
20140134166 | HYPOXIA-RELATED GENE SIGNATURES FOR CANCER CLASSIFICATION - Biomarkers, particularly hypoxia-related genes, and methods using the biomarkers for molecular detection and classification of disease are provided. | 2014-05-15 |
20140134167 | Transforming growth factor-beta (TGF-beta) antagonists for use in treating pain - Provided herein are methods for treating pain and for reducing the excitability of nociceptors, comprising administering a TGF-β antagonist. In some embodiments, a TGF-β antagonist is a monoclonal TGF-f3 neutralizing antibody or a fusion product comprising a monoclonal TGF-β neutralizing antibody, a soluble receptor, an antisense oligodeoxynucleotides (ODNs), a ribozymes, a small inhibitory RNA (siRNA), Smad 6, Smad7, or a small molecule that blocks TGF-β signaling. | 2014-05-15 |
20140134168 | VACCINES BASED ON TARGETING ANTIGEN TO DCIR EXPRESSED ON ANTIGEN-PRESENTING CELLS - The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex. | 2014-05-15 |
20140134169 | Methods of Treating Ovarian Cancer with Dll4 Antagonists - The invention provides methods for treating cancer/tumor growth by administering a Dll4 antagonist, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, optionally with a VEGF antagonist and chemotherapeutic agents. Pharmaceutical compositions and kits containing Dll4 antagonists, VEGF antagonists and chemotherapeutic agents are also provided. | 2014-05-15 |
20140134170 | USE OF INHIBITORS OF EGFR-FAMILY RECEPTORS IN THE TREATMENT OF HORMONE REFRACTORY BREAST CANCERS - Provided are methods of suppressing growth of hormone refractory breast tumors by contacting tumor cells with an ErbB3 inhibitor, preferably an anti-ErbB3 antibody. Also provided are methods for treating hormone refractory breast cancer in a patient by administering to the patient an inhibitor of heregulin binding to ErbB3 or to ErbB2/ErbB3 heterodimer, which inhibitor is an anti-ErbB3 antibody or an anti-ErbB2 antibody. The treatment methods can further comprise selecting a patient having a hormone refractory breast cancer and then administering the inhibitor to the patient. The treatment methods may also comprise administering an estrogen receptor antagonist, or an aromatase inhibitor to the patent and may at further comprise administering to the patient at least one additional anti-cancer agent that is not an ErbB3 inhibitor, an estrogen receptor antagonist, or an aromatase inhibitor to the patient in combination with the ErbB3 inhibitor. | 2014-05-15 |
20140134171 | Dual Variable Domain Immunoglobulins and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 2014-05-15 |
20140134172 | ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF - Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity. | 2014-05-15 |
20140134173 | COMPOSITION AND METHODS OF USE FOR BINDING MOLECULES TO DICKKOPF-1 OR DICKKOPF-4 OR BOTH - Methods of using binding molecules and fragments thereof that bind to the protein target Dickkopf-1 (DKK1), Dickkopf-4 (DKK4) or both (wherein specificity to DKK1 or DKK4 or both is herein denoted as “DKK1/4”) are provided. | 2014-05-15 |
20140134174 | SOGA Polynucleotides and Polypeptides and Uses Thereof - The present invention relates to the identification of polynucleotides and polypeptides involved in insulin and adiponectin signaling and regulation of glucose production. The invention further relates to the use of the identified polynucleotides and polypeptides, and inhibitors of the polynucleotides and polypeptides, in the regulation of glucose production and the monitoring and treatment of metabolic disorders such as diabetes. | 2014-05-15 |
20140134175 | HUMAN ANTIBODIES AGAINST HEPATITIS C VIRUS (HCV) AND USES THEREOF - Isolated human monoclonal antibodies which bind to hepatitis C virus (HCV), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 2014-05-15 |
20140134176 | PLATELET-DERIVED GROWTH FACTOR B SPECIFIC ANTIBODIES AND COMPOSITIONS AND USES THEREOF - The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to PDGF-B. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of PDGF-B mediated diseases, disorders or conditions. | 2014-05-15 |
20140134177 | Compositions and Methods for Treating and Diagnosing Cancer - The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells. | 2014-05-15 |
20140134178 | PHOSPHORYLATION OF HISTONES AND USES THEREOF - Phosphorylation of histones was observed at certain tyrosine residues which have not been associated with epigenetic modification. These sites include H2B Tyr37, H4 Tyr88 and Tyr51 and H3 Tyr99. Kinases responsible for the phosphorylation as well as downstream genes regulated by such phosphorylation were also identified. Antibodies that are specific to such phosphorylated histones have been generated, which are useful for detecting the phosphorylation and related events. With such findings, the present disclosure provides compositions and methods for disease diagnosis, prognosis and therapy selection, in particular for cancer, obesity and diabetes. | 2014-05-15 |
20140134179 | TEM8 ANTIBODIES, CONJUGATES THEREOF, AND THEIR USE - Antibodies that specifically bind TEM8 protein, and conjugates thereof, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell. | 2014-05-15 |
20140134180 | HUMAN MONOCLONAL ANTIBODIES TO O8E - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to O8E with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer. | 2014-05-15 |
20140134181 | Treatment Method For Lung Remodeling Diseases - The present disclosure relates to methods and medicaments useful for pretreatment, treatment, or amelioration of lung remodeling disease. Methods and medicaments for reducing, preventing, or reversing increased lung density, improving lung function, and increasing survivability in subjects having lung remodeling disease are also provided. | 2014-05-15 |
20140134182 | ANTIBODIES OF THE ED-B DOMAIN OF FIBRONECTIN, THEIR CONSTRUCTION AND USES - According to the present invention there is provided a specific binding member which is specific for and binds directly to the ED-B oncofoetal domain of fibronectin (FN). The invention also provides materials and methods for the production of such binding members. | 2014-05-15 |
20140134183 | BINDING MEMBERS TO IL-1 BETA - The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions. | 2014-05-15 |
20140134184 | PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11 (PTPN11) AND TRIPLE-NEGATIVE BREAST CANCER - The present invention relates to a method for treating breast cancer in a subject having a breast cancer of the triple-negative type, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2). The present invention also relates to a method for treating breast cancer in a subject having a breast cancer over-expressing the “SHP2 signature” genes, as compared to normal breast tissue samples, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2), wherein said “SHP2 signature” genes consist of the genes SGCB, ZSCAN12, ID4, ZIC3, CPVL, HLA-A, MCOLN3, SPATA18, TMEM45A, GNAL, CYBRD1, TSPAN7, ZEB1, CNTLN, NEFL, CENPV, ARL6, HPRT1, LRRC34, PDPN, BEND7, SLC16A10, FAM27E1, PLEKHA1, HERC5, CHIC1, PHF6, ELOVL4, ANTXR1, PRAME, SCML1, CLIP4, CECR2, CNOT10, IGF2BP3, NAP1L3, GPC3, KIAA1804, DGKE, FAS, EPHA6, KDELC1, CRISPLD1, DOCK3, ACSL4, CNTNAP3, PLEKHM3, RDX, TBX18, RRAGD, HOXB5, SNCA, FUNDC2, ITGA8, HFM1, IGF2BP2, CCND2, SGTB, MKX, CRYBG3, WBP5, LPHN3, BEX4, CPNE8, GLDC, SLC35F1, HOXA13, SERPINF1, NEFM, SYCP2L, FHL1, APOBEC3C, CALD1, FKBP10, HOXD11, DENND2C, LRRC49, FAM55C, KIAA0408, HOXB9, C160RF62, ACN9, TUSC3, ELOVL2, SPOCK3, HOXB6, WDR35, MPP1, FBX038, PRKAA2, SLAIN1, NPHP3, KIAA1524, PRPS1, GJC1, AMOT, SLC9A6, KCTD12, NUP62CL, DZIP3, JAM3, HOXA9, ANKRD19, CDKN2A, BCAT1, OAT, LPHN2, CCDC82, HSD17B11, SAMHD1, WDR17, STK33, GSTP1, TRPC1, CKB, LIN28B, ALDH1L2, SACS, CLGN, MY03A, EPB41L3, SLC25A27, VCAN, GPX8, GALNT13, PVRL3, MOXD1, HEY1, MAP7D3, ESD, MPP6, EYA4, SPG20, ZDBF2, ZNF204, IFT57, AKR1B1, ADAT2, ZNF717, CCDC88A, ZNF215, MIDI, FBN2, LOC100130876, TCEAL8, IGF2BP1, ANKRD18B, PLAGL1, PM20D2, LDHB, C150RF51, PTPN11, EPB41L2, TLE4, GOLM1, C60RF192, HOXD13, SLIT2, UCHL1, DYNC2H1, CPS1, GPR180, PYGL, NRN1, PRTFDC1, SLC16A1, DSC3, TMC01, LRCH2, SLC6A15, DZIP1, HOXA5, HSPA4L, CDR1, PLS3, ECHDC1, SMARCA1, CXORF57, HOXD10, and IRS4. | 2014-05-15 |
20140134185 | Composition Comprising Inhibitors of IRS-1 and of VEGF - The present invention relates to a composition or kit of parts comprising an inhibitor of IRS-1 and an inhibitor of the VEGF pathway and to the use thereof for treating an angiogenic disease. | 2014-05-15 |
20140134186 | GENETIC POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with Alzheimer's Disease. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 2014-05-15 |
20140134187 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR AUTISM SPECTRUM DISORDERS AND OTHER CONDITIONS - The present invention relates to the field of autism. More specifically, the present invention provides methods for treating individuals with autism spectrum disorders. The present invention also provides methods for predicting a likelihood of ASD. In one embodiment, a method for treating a female patient having a high risk factor of having children with ASD comprises the steps of (a) identifying in a sample taken from the female patient the presence of AT-1 antibodies; and (b) administering an effective amount of an AT-1 inhibitor or inhibitor of AT-1 antibodies to the female patient. | 2014-05-15 |
20140134188 | Methods for P2RY5 Mediated Regulation of Hair Growth and Mutants Thereof - The invention provides for a method for screening compounds that bind to and modulate the hair-specific G-protein coupled receptor, P2RY5. The invention farther provides for methods for controlling hair growth by administering a P2RY5 modulating compound to a subject. | 2014-05-15 |
20140134189 | ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF - The present invention provides antibodies that bind to prokineticin receptors (PROKRs) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PROKR1 and/or PROKR2. The present invention includes antibodies that bind cell surface-expressed PROKR1 and/or PROKR2. In certain embodiments, the antibodies of the present invention are capable of blocking prokineticin (PK)-mediated activation of one or more PROKR. The antibodies of the invention are useful for the treatment of various diseases and disorders mediated by prokineticin signaling. | 2014-05-15 |
20140134190 | BONE MARROW-DERIVED HEMATOPOIETIC PROGENITOR CELLS AND ENDOTHELIAL PROGENITOR CELLS AS PROGNOSTIC INDICATORS FOR CANCER - Methods of determining cancer progression or cancer relapse in a subject at risk for cancer progression or cancer relapse, the methods comprising: obtaining a sample from said subject; measuring the level of VEGFR1 | 2014-05-15 |
20140134191 | TCR Mimic Antibodies as Vascular Targeting Tools - The present invention includes a method of delivering a therapeutic agent into and across an endothelial cell (EC) in a subject in need thereof, comprising: attaching to a T Cell receptor mimic (TCR mimic) an active agent to form a therapeutic agent; and administering to the subject the therapeutic agent in a pharmaceutically acceptable carrier, wherein the therapeutic agent effectively crosses the EC microvascular barrier. Furthermore, the present invention relates to methods of treating diseases (particularly neuronal diseases) or conditions comprising identifying a subject in need of such a treatment and administering to said subject a composition comprising a TCR mimic conjugated to an active agent. | 2014-05-15 |
20140134192 | Methods and Compositions For Wound Treatment - The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use. | 2014-05-15 |
20140134193 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION - The present invention is directed to novel cytotoxic spliceostatin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer. | 2014-05-15 |
20140134194 | HBV EPITOPE REACTIVE EXOGENOUS T CELL RECEPTOR (TCR) AND USES THEREOF - There is provided at least one isolated cell comprising at least one HBV epitope-reactive exogenous T cell receptor and/or fragment thereof, and methods for producing them. In particular, there is provided polynucleotides, constructs and vectors encoding at least one HBV epitope-reactive exogenous T cell receptor for use in the treatment of Hepatitis B Virus (HBV) and Hepatocellular Carcinoma (HCC). The invention further provides kits and methods of detection of HBV and HCC. | 2014-05-15 |
20140134195 | BETA-2 MICROGLOBULIN-DEFICIENT CELLS - The invention provides isolated primate cells preferably human cells that comprise a genetically engineered disruption in a beta-2 microglobulin (B2M) gene, which results in deficiency in MHC class I expression and function. Also provided are the method of using the cells for transplantation and treating a disease condition. | 2014-05-15 |
20140134196 | VACCINE AND METHOD FOR TREATMENT OF NEURODEGENERATIVE DISEASES - Methods and compositions are provided for treatment of neurodegenerative diseases in which there is accumulation of misfolded and/or aggregated proteins, excluding prion diseases. In particular, the invention relates to treatment of the neurodegenerative diseases Huntington's disease (HD), Alzheimer's disease (AD) or Parkinson's disease (PD), by administration of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii). | 2014-05-15 |
20140134197 | Mimotopic Peptides for the Diagnosis and Treatment of Multiple sclerosis - The present invention provides peptides and methods for diagnosing and treating multiple sclerosis and wherein the method can also be applicable to the diagnosis and treatment of other immune disorders. | 2014-05-15 |
20140134198 | EPHA2 T-CELL EPITOPE AGONISTS AND USES THEREFORE - EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods. | 2014-05-15 |
20140134199 | FUSION PROTEIN COMPRISING DIPTHERIA TOXIN NON-TOXIC MUTANT CRM197 OR FRAGMENT THEREOF - Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid. | 2014-05-15 |
20140134200 | HLA-A* 1101-RESTRICTED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - An HLA-A*1101-restricted WT1 peptide, specifically, a peptide comprising an amino acid sequence consisting of 9 contiguous amino acids from a WT1 protein, wherein the peptide has an ability to bind to an HLA-A*1101 molecule, and has an ability to induce a CTL is described. A peptide dimer having an ability to bind to an HLA-A*1101 molecule and having an ability to induce a CTL, in which two peptide monomers each comprising an amino acid sequence consisting of 9 contiguous amino acids from a WT1 protein and comprising at least one cysteine residue are bound to each other through a disulfide bond is also described. Furthermore, a polynucleotide encoding the peptide, a pharmaceutical composition for the treatment and/or prevention of a cancer comprising the same and the like are provided. | 2014-05-15 |
20140134201 | RECOMBINANT VACCINES AND USE THEREOF - The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule. | 2014-05-15 |
20140134202 | VACCINES AND IMMUNOPOTENTIATING COMPOSITIONS AND METHODS FOR MAKING AND USING THEM - An immunopotentiating composition comprising a papaya mosaic virus (PapMV), or a virus-like particle (VLP) derived from PapMV coat protein, which is capable of functioning as an adjuvant and thus potentiating an immune response in an animal is provided. The immunopotentiating composition can further comprise an immunogen, which can be fused or otherwise linked to the VLP, or not linked to the VLP. The immunopotentiating composition is capable of potentiating a humoral and/or a cellular response in the animal and is suitable for use as an adjuvant or vaccine. Methods of potentiating an immune response in an animal comprising administering to the animal an immunopotentiating composition are also provided have application in both human and veterinary medicine. | 2014-05-15 |
20140134203 | Respiratory Syncytial Virus (RSV) Sequences For Protein Expression and Vaccines - The invention provides RSV fusion (F) protein ectodomain polypeptide sequences and nucleotide sequences encoding them, as well as cells containing the invention's polypeptide and nucleotide sequences. The invention further provides VLPs that contain the invention's polypeptides, and methods for using the VLPs for protein expression and vaccine formulation. Also provided are methods for distinguishing between subjects immunized with the invention's compositions and subjects infected with RSV. | 2014-05-15 |
20140134204 | METHODS OF IMPROVING VACCINE IMMUNOGENICITY - The present invention provides a process called “Immune Banking” that enhances vaccine efficacy by exploiting existing humoral responses. The process involves tagging new antigens with molecular markers recognized by an existing antibody response. This recognition of the tagged vaccine components enhances adaptive immune responses to the new vaccine. | 2014-05-15 |
20140134205 | COMPOSITIONS, METHODS AND USES FOR DENGUE VIRUS SEROTYPE-4 CONSTRUCTS - Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions. | 2014-05-15 |
20140134206 | INFLAMMATION AND IMMUNITY TREATMENTS - Therapeutic use of extracts containing proanthocyanidin including treating disorders, e.g., inflammatory disorders, e.g., inflammatory bowel disease, Crohn's disease, ulcerative colitis, indeterminate colitis, microscopic colitis, collagenous colitis, and irritable bowel syndrome. Methods of increasing a subject's immunological resistance to an infection and/or treating the infection. The infection can be, e.g., a bacterial, viral, or fungal infection. The methods can include, e.g., selecting a subject that has, or is at risk of developing, an infection, e.g., a bacterial, viral, or fungal infection, or a combination thereof; providing a composition comprising at least about 10% proanthocyanidin by weight; and administering to the subj ect an amount of the composition to the subject, to thereby increase a subject's immunological resistance to an infection and/or to treat the infection. | 2014-05-15 |
20140134207 | RECOMBINANT RIFT VALLEY FEVER (RVF) VIRUSES AND METHODS OF USE - Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus. | 2014-05-15 |
20140134208 | MULTI PLASMID SYSTEM FOR THE PRODUCTION OF INFLUENZA VIRUS - Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. A method of producing a cold adapted (ca) influenza virus that replicates efficiently at, e.g., 25° C. (and immunogenic compositions comprising the same) is also provided. | 2014-05-15 |
20140134209 | METHOD FOR PRODUCING VACCINAL VIRAL STRAIN OF A VIRUS OF THE REOVIRIDAE FAMILY - The invention relates to a method for producing a modified viral strain of a virus which is a member of the Reoviridae family and, in particular, relates to vaccinal viral strains of the Orbivirus genus. | 2014-05-15 |
20140134210 | COMPOSITION CONTAINING ANTIBIOTICS AND LYSOPHOSPHATIDYLCHOLINE FOR BOOSTING IMMUNITY OR TREATMENT OF BACTERIAL INFECTIONS - The present invention relates to: a pharmaceutical composition containing lysophosphatidylcholine or analogs thereof and antibiotics as active ingredients for boosting immunity or the treatment of bacterial infections; a method for boosting immunity or the treatment of bacterial infections, which comprises a step for administering the composition; and a kit containing the composition for boosting immunity or the treatment of bacterial infections. | 2014-05-15 |
20140134211 | Formulations and Methods for Recovery From Dental Surgery - Methods and formulations for the improvement of recovery following bone-impacting injury or surgery. The formulations disclosed herein preferably include a blood component with a pharmaceutical agent. The blood component is preferably whole blood or platelet-rich plasma. The pharmaceutical agent may be a glucocorticoid hormone or other organic pharmaceutical agent. Particularly preferred pharmaceutical agents include dexamethasone, triamcinolone hexacetonide, melatonin, purmorphamine, 17β-estradiol, vitamin K | 2014-05-15 |
20140134212 | MINCED CARTILAGE SYSTEMS AND METHODS - Compositions comprising a plurality of cartilage particles from a human adult cadaveric donor, wherein the cartilage particles comprise viable chondrocytes, and a biocompatible carrier are provided. Methods of manufacturing cartilage compositions comprising a plurality of cartilage particles from a human adult cadaveric donor are also provided. | 2014-05-15 |
20140134213 | TREATMENT OF MICROBIAL INFECTIONS - The present application relates to an anti-microbial system for use in the treatment of microbial infections or control of microbial contamination, which avoids the use of antibiotics. Such infections include mastitis, tuberculosis, cystic fibrosis and the contamination that may result from biofilm formation on medical devices. | 2014-05-15 |
20140134214 | MEANS AND METHODS OF STERILIZATION OF BIOFUNCTIONAL COMPOSITIONS - The present invention, inter alia, relates to a closed sterilized container comprising at least one carrier which is a stabilizer; and at least one biomolecule reversibly attached to the carrier, wherein said carrier partially or completely covers the attached biomolecules and wherein said at least one carrier is selected from the group consisting of (poly)peptides such as dipeptides or tripeptides, amino acids, polyalcohols, polyethyleneglycols, ionic liquids, compatible solutes, saponins and a mixture thereof. The invention also relates to methods for producing sterilized containers according to the invention and uses thereof. | 2014-05-15 |
20140134215 | PIGMENTS HAVING IMPROVED COLORING CAPABILITY - The embodiments relate to cosmetic compositions providing high coloring pigment particles capable of achieving high color coverage with less pigment. The compositions of embodiments include aluminum hydroxide particles coated with at least one pigment, and having an average coated ratio of from about 20% to about 100% pigment by weight of aluminum hydroxide, and a cosmetically acceptable carrier. The compositions may be useful as a foundation and/or as a composition to correct skin discoloration. | 2014-05-15 |
20140134216 | IRON OXIDE RED PIGMENT - Disclosed are a hematite composite formed by aggregation of fine particles, each of the fine particles comprising a crystalline hematite particle and phosphorus-containing amorphous silicate covering the surface of the crystalline hematite particle; a pigment comprising the hematite composite; a cosmetic composition comprising a cosmetic pigment containing the hematite composite and a cosmetic base; and a method for producing the hematite composite, comprising the step of heat-treating an amorphous and/or microcrystalline iron oxide containing silicon and phosphorus. | 2014-05-15 |
20140134217 | LEAVE-ON COMPOSITIONS CONTAINING CELLULOSE MATERIALS - The compositions and methods of this invention relate to a leave-on skin care composition containing hydrophobic, linear cellulose particles having an average length of from about 1 to about 500 μm, a particle aspect ratio from about 2 to about 25 and an average thickness of from about 1 to about 500 μm; and a cosmetically acceptable carrier. | 2014-05-15 |
20140134218 | RINSE-OFF SKIN CARE COMPOSITIONS CONTAINING CELLULOSIC MATERIALS - The compositions and methods of this invention relate to a rinse-off skin care composition containing hydrophobic, linear cellulose particles having an average length of from about 1 to about 1000 μm, a particle aspect ratio from about 1000 to about 2 and a thickness of from about 1 to about 500 μm; at least one cleansing agent selected from the group consisting of a saponified fat and a surfactant; and a cosmetically acceptable carrier. | 2014-05-15 |
20140134219 | SKIN CARE COMPOSITIONS CONTAINING COTTON AND CITRUS-DERIVED MATERIALS - The compositions and methods of this invention relate to skin care compositions containing: (a) hydrophobic and hydrophilic, linear cellulose particles having an average length of from about 1 to about 1000 μm, a particle aspect ratio from about 1000 to about 2 and a thickness of from about 1 to about 500 μm; (b) amphiphilic linear cellulose particles derived from sources selected from the following group: citrus pulp, sugar beet pulp, banana pulp, mango pulp, apple pulp, passion fruit pulp and tomato pulp and the like, said particles having an average size of from about 1 to about 1000 μm, a particle aspect ratio from about 1000 to about 2 and a thickness of from about 1 to about 500 μm; wherein the ratio of ingredient (b) to ingredient (a) is from about 1:10 to about 10:1; and a cosmetically acceptable carrier. | 2014-05-15 |
20140134220 | High-Glass Transition Temperature Absorbable Microspheres - Absorbable microspheres comprising a copolymer formed from greater than 80 to about 99 mole percent D,L-lactide, L(−)-lactide, D(+)-lactide, or meso-lactide and combinations thereof, and about 1 to less than 20 mole percent of a different second monomer selected from the group consisting of p-dioxanone and trimethylene carbonate and combinations thereof, said microspheres having a particle size ranging from about 5 to 2000 microns. Also described herein are formulations comprising such absorbable microspheres. | 2014-05-15 |
20140134221 | AGENT FOR PROVIDING POSITIVE SURFACE CHARGE ON UV PROTECTION VESICLES - In order to prepare a UV protective agent for topical application to the skin or hair with very high UV filter substance concentration and with good adhesion to the skin and hair, according to the invention the UV protective agent is proposed with at least one UV filter substance, which is encapsulated in a vesicular carrier system, in which the UV protective agent is characterized by the fact that the at least one UV filter substance encapsulated in the vesicular carrier system is lipophilic and the vesicular carrier system consists of vesicles constructed from hydrophobized polysaccharides and having a particle size from 10 to 1000 nm, as well as a positive surface charge with a zeta potential in the range from 1 to 150 mV by means of the charge donors contained therein. In addition, use of such a UV protective agent in corresponding cosmetic and/or pharmaceutical formulations is proposed. | 2014-05-15 |
20140134222 | TOPICAL BENFOTIAMINE AND PYRIDOXAMINE COMPOSITIONS - The present invention provides a composition comprising an effective amount of benfotiamine and an effective amount of pyridoxamine in a suitable vehicle for topical application. The present compositions are useful in improving the appearance of aged skin characterized by wrinkles, loss of elasticity, and hyperpigmentation caused by chronoaging and/or photoaging of skin, by inhibiting particularly skin damage resulting from reactive carbonyl species (RCS), glycation of skin proteins, formation of advanced glycation endproducts (AGEs) and formation of advanced lipoxidation endproducts (ALEs). | 2014-05-15 |
20140134223 | POLYMERIC FILM FOR AGRICULTURAL PRODUCT STORAGE, CONTAINERS MADE THEREFROM AND RELATED METHODS OF AGRICULTURAL PRODUCT STORAGE - The present invention includes polymeric laminate materials, containers made from same and methods for the storage of agricultural products and the like. | 2014-05-15 |
20140134224 | STABLE COMPOSITION OF HOCI, A PROCESS FOR ITS PRODUCTION AND USES THEREOF - A stable antimicrobial aqueous hypochlorous acid solution that retains its activity for at least three months and can be provided with high levels of hypochlorous acid (more than 500 ppm), the aqueous hypochlorous acid composition having low chloride concentrations (maximum chloride levels of 1:3 chloride to hydrochlorous acid) and a pH between 3.5 and 7.0 to stabilise the composition without the need for additional stabilisers. A solid composition is also provided for producing the stable solution. | 2014-05-15 |
20140134225 | Drug/Drug Delivery Systems For The Prevention And Treatment Of Vascular Disease - A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity. | 2014-05-15 |
20140134226 | COMPOSITIONS AND METHODS FOR INHIBITING BONE GROWTH - Compositions and methods are provided for a matrix that inhibits bone growth in a patient in need thereof. In one embodiment, a method of inhibiting bone growth is provided, the method comprising: implanting a matrix at a target tissue site, the matrix comprising a biodegradable polymer and dextran loaded in the matrix in an amount of from about 5% to about 95% by weight based on a total weight of the matrix. | 2014-05-15 |